Discovery of VU2957 (Valiglurax): An mGlu(4) Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease

[Image: see text] Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu(4) PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. To advance toward the clinic, a spr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ACS Med Chem Lett
Egile Nagusiak: Panarese, Joseph D., Engers, Darren W., Wu, Yong-Jin, Bronson, Joanne J., Macor, John E., Chun, Aspen, Rodriguez, Alice L., Felts, Andrew S., Engers, Julie L., Loch, Matthew T., Emmitte, Kyle A., Castelhano, Arlindo L., Kates, Michael J., Nader, Michael A., Jones, Carrie K., Blobaum, Anna L., Conn, P. Jeffrey, Niswender, Colleen M., Hopkins, Corey R., Lindsley, Craig W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Chemical Society 2018
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6421540/
https://ncbi.nlm.nih.gov/pubmed/30891122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.8b00426
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak